亚洲欧美精品在线-亚洲欧美精品中文字幕在线观看-亚洲欧美精品综合在线观看-亚洲欧美精选-亚洲欧美久久-亚洲欧美久久精品

Hello! Welcome to the official website of Betta Pharmaceuticals!
Service Hotline:+86-571-86130357     Add to Favorites | Online Feedback 中文


Icotinib hydrochloride is a National Class 1.1 new drug that is independently developed by Betta Pharmaceuticals Co., Ltd. for nearly a decade. It is also China's first small molecule targeted anti-cancer drug. Icotinib is a potent and highly selective oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and it is used for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients carrying EGFR mutations. 
On June 7th, 2011, Icotinib hydrochloride was approved by the National Medical Products Association (NMPA), fulfilling the unmet medical needs in China.
On August 12th, 2011, the market launch of Icotinib hydrochloride was held in the Great Hall of the People in Beijing. It was praised as a groundbreaking scientific and technological achievement in the China healthcare industry.
In 2012, Icotinib hydrochloride was included on Citeline’s “Pharm R&D Annual Review for 2012”, which was the first time a Chinese innovative drug was included on such report.
On August 13th, 2013, the phase III ICOGEN clinical trial results of Icotinib hydrochloride were published on the Lancet Oncology (Shi, Y., et al., The Lancet Oncology 14 (10) p953-961). Professor of the University of Colorado, Dr. David Camidge, commented that Icotinib has opened a new era of anticancer drug research in China, which is a significant milestone in the global oncology research.

1698306007803090.png

In 2012 and 2014, icotinib hydrochloride won the Golden Prize of Chinese Patent Award for its composition of matter and the crystal form patents.
In 2015, icotinib hydrochloride won “First Prize of National Science and Technology Progress Award 2015”.
In 2016, icotinib hydrochloride won “Chinese Industry Award”. In the same year, it was included in the first round of the price negotiation with the Chinese National Health Commission and created a new model for medical insurance negotiation, which reduced the burden of Chinese patients.
In 2017, icotinib hydrochloride was enlisted on the National Reimbursement Drug List (NRDL). On July 19th, the BRAIN clinical study results of icotinib hydrochloride for NSCLC brain metastasis treatment were published in the Lancet Oncology (Jin-Ji, Y., et al., The Lancet Oncology 5 (9) p707-716). It is the first phase III study of EGFR TKI targeting NSCLC patients with brain metastasis, and this treatment is recommended in the clinical guide. On August 23rd, the first-line clinical study of icotinib hydrochloride in NSCLC patients carrying EGFR mutations was published in the Annual of Oncology, which provided clinical support for its use in the first-line setting.
In 2018, icotinib hydrochloride was included on the National Essential Drug List (EDL), giving access to more Chinese patients.
In 2019, icotinib hydrochloride was included on the General Drug Access Catalogue of National Medical Insurance, further reducing the economic burden of NSCLC patients.



1.png

主站蜘蛛池模板: 狼狼躁日日躁夜夜躁A片 | 亚洲色欧美图另类综合 | 亚洲爆乳无码一区二区三区 | 一本二本黄色网站 | 亚洲丁香婷婷综合久久六月 | 四虎天堂| 99久久无码午夜体验区 | 忘忧草影院在线www韩国日本 | 激情六月综合 | 国产av无码专区亚汌a√ | 亚洲一级毛片视频 | 久久青草国产手机看片福利盒子 | 国产三级做爰在线播放 | 狠狠干夜夜夜 人人干天天日天天干 | 精品久久久无码人妻中文字幕麻 | 欧美日韩国产一区在线 | 国产福利不卡在俺也去亚洲 | 激情五月婷婷在线 | 国产成人无码av一区二区 | 国产精品三级电影在线观看 | 国97视频在线观看免费 | 国产午夜鲁丝无码拍拍 | 色情.WWW成人天堂 | 日韩aⅴ人妻无码 | 爱爱帝国亚洲综合社区区 | 精品AV无码片 | 国产精品亚洲色婷婷久久99精品 | 18禁黄污吃奶免费看 | 99久久婷婷国 | 四虎库影必出精品8848 | 国产色无码精品视频国产 | 久久中文精品视频 | 视频一本大道香蕉久在线播放 | 91无套极品外围在线播放 | 久久久久久久99精品免费观 | 中文字幕国产91在线手机版 | 日韩亚州欧美中文字幕 | 99久久国产自偷自偷免费一区 | 亚洲v男人的天堂网址在线观看 | 欧美精品一区二区 | 人体射精一区二区 |